Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis.
To estimate the cost-effectiveness of the levonorgestrel intrauterine device (IUD) as an endometrial cancer prevention strategy in obese women.



A modified Markov model was used to compare IUD placement at age 50 with usual care among women with a body mass index (BMI, kg/m) 40 or greater or BMI 30 or greater. The effects of obesity on incidence and survival were incorporated. The IUD was assumed to confer a 50% reduction in cancer incidence over 5 years. Costs of IUD and cancer care were included. Clinical outcomes were cancer diagnosis and deaths from cancer. Incremental cost-effectiveness ratios were calculated in 2015 U.S. dollars per year of life saved. One-way and two-way sensitivity analyses and Monte Carlo probabilistic analyses were performed.



For a 50 year old with BMI 40 or greater, the IUD strategy is costlier and more effective than usual care with an incremental cost-effectiveness ratio of $74,707 per year of life saved. If the protective effect of the levonorgestrel IUD is assumed to be 10 years, the incremental cost-effectiveness ratio decreases to $37,858 per year of life saved. In sensitivity analysis, a levonorgestrel IUD that reduces cancer incidence by at least 68% in women with BMIs of 40 or greater or costs less than $500 is potentially cost-effective. For BMI 30 or greater, the incremental cost-effectiveness ratio of IUD strategy is $137,223 per year of life saved compared with usual care. In Monte Carlo analysis, IUD placement for BMI 40 or greater is cost-effective in 50% of simulations at a willingness-to-pay threshold of $100,000 per year of life saved.



The levonorgestrel IUD is a potentially cost-effective strategy for prevention of deaths from endometrial cancer in obese women.
Divisions of Gynecologic Oncology and Clinical and Epidemiologic Research, Department of Obstetrics and Gynecology, Duke Clinical Research Institute, and the Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Joseph A
JA
Dottino
Vic
V
Hasselblad
Angeles Alvarez
AA
Secord
Evan R
ER
Myers
Junzo
J
Chino
Laura J
LJ
Havrilesky
D015992:Body Mass Index; D003271:Contraceptive Agents, Female / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016889:Endometrial Neoplasms / Q000191:economics / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000191:economics*; D016912:Levonorgestrel / Q000191:economics* / Q000627:therapeutic use*; D008875:Middle Aged; D018803:Models, Economic; D009010:Monte Carlo Method; D009765:Obesity / Q000150:complications*
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel